[Antithymocyte globulin as conditioning regimen for bone marrow transplantation]

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Context:

• Bone marrow transplantation (BMT) is a critical treatment for hematological malignancies and other diseases.
• Antithymocyte globulin (ATG) is used as part of conditioning regimens to prevent graft rejection and graft-versus-host disease (GVHD).
• Evaluating the safety and efficacy of ATG in unrelated or mismatched donor BMT is essential.

Purpose:

• To assess the safety and efficacy of antithymocyte globulin (ATG) as part of a conditioning regimen in patients undergoing bone marrow transplantation with HLA-compatible unrelated or mismatched donors.
• To compare outcomes, including adverse reactions, graft failure, GVHD, infections, and relapse rates, between patients receiving ATG and those not receiving ATG.

Summary:

• Eight patients received ATG during BMT; only one experienced side effects requiring discontinuation.
• No graft failure or acute GVHD was observed in patients receiving ATG.
• While lymphocyte subsets (CD3, CD4, CD8, CD20) remained comparable, ATG use was associated with increased cytomegalovirus infections and higher relapse rates in hematological malignancy.
• Platelet counts were generally stable, though platelet infusions were not always effective.

Impact:

• ATG appears to be well-tolerated and effective in preventing graft failure and acute GVHD in unrelated/mismatched BMT.
• The increased risk of cytomegalovirus infection and relapse warrants careful monitoring and potential prophylactic strategies in patients receiving ATG.
• Further research is needed to optimize ATG use and mitigate associated risks for improved BMT outcomes.